ArticleNature materials2011
The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers.
Article in Nature materials, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 261 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
261 citing papers in PubMed.
- Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe.Science translational medicine · 2014Trial
- Global research hotspots and evolving themes in chemoresistance of hepatocellular carcinoma: a bibliometric analysis from a pharmacological perspective.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Biomimetic nanoparticles in cancer photodynamic therapy: a review of targeted delivery systems and therapeutic outcomes.Beilstein journal of nanotechnology · 2026Review
- Current Status and Emerging Trends in Global Research on Liposome Therapy for Hepatocellular Carcinoma: A Bibliometric Analysis.Journal of hepatocellular carcinoma · 2026Article
- Development of a nanoparticle-based immunotherapy targeting CD137 for nasopharyngeal carcinoma treatment.Theranostics · 2026Article
- Transcytotic transportation of size-controlled nanocarriers into dystrophic skeletal muscle leads to therapeutic outcome in mice.Nature communications · 2025Article
- Precise Ratiometric Drug Delivery for the Treatment of Triple-Negative Breast Cancer.ACS nano · 2025Article
- Chemokine/cytokine-releasing biomaterials induce in situ tertiary lymphoid-like structures and enhance antitumor immunity.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Longer Acting Injectable: Continuous, Linear Release of a Progestin Contraceptive From an Oxidized Porous Silicon Host.Advanced healthcare materials · 2025Article
- Probiotic-Enhanced Porous Bio-Hybrids with Inflammatory Targeting, ROS Scavenging, and Long-Term Drug Release for Ulcerative Colitis Treatment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Unlocking tumor barrier: annexin A2-mediated transcytosis boosts drug delivery in pancreatic and breast tumors.Nature communications · 2025Article
- Advanced Nanomaterials Functionalized with Metal Complexes for Cancer Therapy: From Drug Loading to Targeted Cellular Response.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Functional diversity of cardiac macrophages in health and disease.Nature reviews. Cardiology · 2025Review
- Insights into the history and trends of nanotechnology for the treatment of hepatocellular carcinoma: a bibliometric-based visual analysis.Discover oncology · 2025Article
- Membrane Fusion-Based Drug Delivery Liposomes Transiently Modify the Material Properties of Synthetic and Biological Membranes.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Advanced Immunomodulatory Biomaterials for Therapeutic Applications.Advanced healthcare materials · 2025Review
- Bioinspired Extracellular Vesicles for Enhanced Delivery of siRNA to Tumors.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Research Trends on Nanomaterials and Hepatocellular Carcinoma From 1999 to 2024: A Bibliometric Analysis.Drug design, development and therapy · 2025Article
- Biomimetic Materials to Fabricate Artificial Cells.Chemical reviews · 2024Review
- Advanced Porous Nanomaterials: Synthesis, Properties, and Applications.Nanomaterials (Basel, Switzerland) · 2024Article
201 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
21 authors.
Funding
Abstract
Encapsulation of drugs within nanocarriers that selectively target malignant cells promises to mitigate side effects of conventional chemotherapy and to enable delivery of the unique drug combinations needed for personalized medicine. To realize this potential, however, targeted nanocarriers must simultaneously overcome multiple challenges, including specificity, stability and a high capacity for disparate cargos. Here we report porous nanoparticle-supported lipid bilayers (protocells) that synergistically combine properties of liposomes and nanoporous particles. Protocells modified with a targeting peptide that binds to human hepatocellular carcinoma exhibit a 10,000-fold greater affinity for human hepatocellular carcinoma than for hepatocytes, endothelial cells or immune cells. Furthermore, protocells can be loaded with combinations of therapeutic (drugs, small interfering RNA and toxins) and diagnostic (quantum dots) agents and modified to promote endosomal escape and nuclear accumulation of selected cargos. The enormous capacity of the high-surface-area nanoporous core combined with the enhanced targeting efficacy enabled by the fluid supported lipid bilayer enable a single protocell loaded with a drug cocktail to kill a drug-resistant human hepatocellular carcinoma cell, representing a 10(6)-fold improvement over comparable liposomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.